De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers

INTRODUCTION: Anaplastic lymphoma kinase (ALK) rearranged lung adenocarcinomas are responsive to the multitargeted ALK inhibitor crizotinib. One of the common mechanisms of resistance to crizotinib is the acquisition of ALK kinase domain mutations. However, the presence of ALK mutations in crizotini...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Lung Cancer
Autores principales: Lucena-Araujo, Antonio R., Moran, Jason P., VanderLaan, Paul A., Dias-Santagata, Dora, Folch, Erik, Majid, Adnan, Kent, Michael S., Gangadharan, Sidharta P., Rangachari, Deepa, Huberman, Mark S., Kobayashi, Susumu S., Costa, Daniel B.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5002311/
https://ncbi.nlm.nih.gov/pubmed/27565908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2016.06.006
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares